• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Does HPV Vaccination Reduce Risk of CIN Recurrence After Local Excision?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Human papillomavirus (HPV) vaccination becomes less cost-effective after women reach age 26
  • However, Women >26 years who are at high risk of HPV infection and undergoing surgical treatment for CIN may benefit from adjuvant HPV vaccination
  • Kechagias et al. (BMJ, 2022) explored the efficacy of HPV vaccination among individuals undergoing local surgical treatment for preinvasive genital disease

METHODS:

  • Systematic review and meta-analysis
  • Inclusion criteria
    • All studies that reported on the risk of HPV infection and recurrence of disease related to HPV infection after local surgical treatment of preinvasive genital disease in individuals who were vaccinated
  • Study design
    • For meta-analysis, only included studies that also reported results from non-vaccinated cohort
    • For primary outcome, data from observational studies and RCTs were pooled if they included efficacy of vaccination when given shortly before, at the time of, or up to 12 months after the local surgical treatment
    • Pooled risk ratios and 95% confidence intervals were calculated with a random effects meta-analysis model
    • GRADE criteria used to assess evidence quality
  • Primary outcome
    • Risk of recurrence for CIN2+ after local surgical treatment
  • Secondary outcomes
    • Risk of HPV infection
    • Risk of other lesions related to HPV infection

RESULTS:

  • 22 studies
    • 18 with a non-vaccinated control group were used in meta-analysis
  • Risk of recurrence of CIN2+ was reduced in individuals who were vaccinated compared with those who were not vaccinated
    • RR 0.43 (95% CI, 0.30 to 0.60)
    • Median follow-up: 36 (IQR, 24 to 43.5) months
    • 11 studies | 19,909 participants
  • Effect estimate was stronger when the risk of recurrence of CIN2+ was assessed for disease related to HPV subtypes HPV16 or HPV18
    • RR 0.26 (95% CI, 0.16 to 0.43)
    • 6 studies | 1879 participants
  • Confidence in evidence ranged from very low to moderate
    • Likely due to publication bias and inconsistency in the studies included
  • The risk of recurrence of CIN3 was also reduced in patients who were vaccinated but uncertainty was large
    • RR 0.28 (95% CI, 0.01 to 6.37)
    • 3 studies | 17,757 participants
  • Evidence of benefit was lacking for recurrence of
    • Vulvar, vaginal, and anal intraepithelial neoplasia
    • Genital warts
    • Persistent and incident HPV infections

CONCLUSION:

  • HPV vaccination might reduce the risk of CIN recurrence in individuals treated with local surgical excision, especially if the disease is related to HPV16 or HPV18
  • The number of studies and participants for non-cervical intraepithelial neoplasia and warts was low
  • High quality RCTs are needed to establish effectiveness of HPV vaccination in individuals undergoing treatment for HPV-related diseases
  • The authors state

The NOVEL (Nonavalent Prophylactic HPV Vaccine (Gardasil 9) After Local Conservative, NCT03979014) trial, an ongoing, large, appropriately powered randomised controlled trial, is expected to report results and give further insight on the effect of Gardasil 9 on persistent incident, recurrent, and prevalent HPV infections and cost effectiveness

If the study reports benefit, the results could be applicable to women with multifocal disease, other diseases related to HPV infection, and individuals with a diagnosis of malignancies related to HPV infection

Learn More – Primary Sources:

Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

RCT Results: Does HPV Vaccination “Unmask” Lesions Due to Non-Vaccine-Preventable HPV Types?
Effects of HPV Vaccination Programs: The Latest Updated Meta-Analysis
England’s Early HPV Vaccination Program Substantially Reduced Incidence of Cervical Cancer and CIN3
Beyond High-Risk Lesions: HPV Vaccination and Impact on Invasive Cervical Cancer Risk

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site